Why Novavax, Inc.’s (NVAX) Stock Is Up 6.20%
As of Tuesday, September 22, Novavax, Inc.’s NVAX share price has surged by 6.20%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Commentary & Analysis
Why Novavax, Inc.’s (NVAX) Stock Is Up 9.09%
As of Thursday, September 17, Novavax, Inc.’s NVAX share price has surged by 9.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Novavax, Inc.’s (NVAX) Stock Is Down 7.16%
As of Thursday, September 10, Novavax, Inc.’s NVAX share price has dipped by 7.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Novavax, Inc.’s (NVAX) Stock Is Up 5.44%
As of Tuesday, September 01, Novavax, Inc.’s NVAX share price has surged by 5.44%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Novavax, Inc.’s (NVAX) Stock Is Up 5.83%
As of Monday, August 31, Novavax, Inc.’s NVAX share price has surged by 5.83%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NVAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,753.4 | $257.9 | 52% |
|
| Shares Out (Mil) | 164.6 | 54.3 | 72% |
|
| Institutional Ownership | 98.6% | 92.9% | 80% |
|
| Float (Mil) | 142.5 | 41.4 | 68% |
|
| Beta | 2.42 | 0.95 | 96% |
|
| Avg Daily Volume (000s) | 5,732 | 674 | 92% |
|
| Price Change (52-week) |
23.0% | 51.5% | 69% |
|
| Growth | NVAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.8% | 13.2% | 79% |
|
| Net Income (5yr) | 25.0% | (10.1%) | 80% |
|
| EPS (5yr) | 18.7% | 15.8% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (15.6%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 2 | 2 | |
| Current EPS | ($0.400) | ($0.427) | ($0.614) | |
| Month Ago EPS | ($0.400) | ($0.860) | ($0.614) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.320) | ($0.417) | ($0.543) | |
| Year/Year Chg | 23.5% | (116.6%) | (95.0%) | |
| Financials | NVAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $414 | $37 | 39% |
|
| Net Income (TTM) (Mil) | ($248) | ($43) | 6% |
|
| EPS (TTM) | ($1.518) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($32) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($73) | $2 | 17% |
|
| Long-Term Debt (Q1) (Mil) | $293 | $4 | 53% |
|
| Enterprise Value (Q1) (Mil) | $1,071 | $174 | 42% |
|
| Valuation | NVAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NVAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (2.6%) | 68.9% | 4% |
|
| Net Margin | (59.9%) | (72.5%) | 10% |
|
| ROA | (21.6%) | (47.7%) | 20% |
|
| ROE | 323.7% | (54.9%) | 99% |
|
| Liabilities to Assets | 120.0% | 29.1% | 97% |
|
| F-Score | 1 | 3 | 1% |
|
Novavax, Inc. did not pass any screens on 9/25/2026.
